MedTrace Logo

Norwegian Coronavirus Disease 2019 Study

NCT04316377 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2020-06-05

No results posted yet for this study

Summary

In the current proposal, the investigators aim to investigate the virological and clinical effects of chloroquine treatment in patients with established COVID-19 in need of hospital admission. Patients will be randomized in a 1:1 fashion to standard of care or standard of care with the addition of therapy with chloroquine.

Conditions

  • Corona Virus Infection

Interventions

DRUG

Hydroxychloroquine Sulfate

400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days

Sponsors & Collaborators

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Olav Dalgard, MD PhD · Akerhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-25
Primary Completion
2020-05-25
Completion
2025-03-03

Countries

  • Norway

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04316377 on ClinicalTrials.gov